Valeant Pharmaceuticals, based in Quebec, Canada, has acquired ophthalmic products company Bausch + Lomb for $8.7 billion, according to a CNN Money report.
Warburg Pincus, private equity firm, received $4.5 billion in the acquisition deal. The other $4.2 billion of Valeant's payment was used to cover Bausch + Lomb's outstanding debt.
Valeant's acquisition is a step in the company's efforts to expand in the ophthalmology market.
More Articles on Ophthalmology:
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
FDA Approves Bausch + Lomb TRULIGN Astigmatism Correction Lens
Dr. Eva Liang Opens Center for Sight in Las Vegas
Warburg Pincus, private equity firm, received $4.5 billion in the acquisition deal. The other $4.2 billion of Valeant's payment was used to cover Bausch + Lomb's outstanding debt.
Valeant's acquisition is a step in the company's efforts to expand in the ophthalmology market.
More Articles on Ophthalmology:
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
FDA Approves Bausch + Lomb TRULIGN Astigmatism Correction Lens
Dr. Eva Liang Opens Center for Sight in Las Vegas